A retrospective cohort analysis by Riley et al. [73] demonstrated that GLP-1 RA therapy significantly lowered the risk of major cardiovascular events, including acute MI and HF, in T2DM patients over five years compared with those receiving insulin alone. The gene discussed is GLP1R; the disease is hydrops fetalis.